alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-END>                               SEP-30-1995
<CASH>                                           6,426
<SECURITIES>                                         0
<RECEIVABLES>                                    2,738
<ALLOWANCES>                                     (384)
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                         197,840
<DEPRECIATION>                               (161,769)
<TOTAL-ASSETS>                                  47,929
<CURRENT-LIABILITIES>                                0
<BONDS>                                        118,824
<COMMON>                                             0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                   (141,714)
<TOTAL-LIABILITY-AND-EQUITY>                    47,929
<SALES>                                              0
<TOTAL-REVENUES>                                47,640
<CGS>                                                0
<TOTAL-COSTS>                                   21,425
<OTHER-EXPENSES>                                 6,440
<LOSS-PROVISION>                               (1,163)
<INTEREST-EXPENSE>                               7,999
<INCOME-PRETAX>                                (3,751)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (3,751)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (3,751)
<EPS-PRIMARY>                                        0<F1>
<EPS-DILUTED>                                        0<F1>
<FN>
<F1>Not presented because the company operates as a limited partnership.
</FN>
        

</TABLE>
Timothy WALLACE, petitioner, v. Ray HOBBS, Director, Arkansas Department of Correction.

No. 12-9898.

Supreme Court of the United States

June 10, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Eighth Circuit denied.
Evaristus MACKEY, petitioner, v. David BERKEBILE, Warden.

No. 12-10206.

Supreme Court of the United States

June 10, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Sixth Circuit denied.
Robert Wayne HOLSEY, petitioner, v. Carl HUMPHREY, Warden.

No. 12-9659.

Supreme Court of the United States

June 10, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.
Your patients have questions 

about generics.

Will they work the same?

Why do they look different?

Why do they cost less?

Let FDA help you with the answers.

Talk to your patients about generics.

You can help them trust the medications you prescribe.

FDA follows a rigorous review process of testing and monitoring generics and 

inspecting manufacturing facilities to ensure they have the same safety, efficacy, 

and quality as brand-name medications. 

www.fda.gov/GenericDrugs
Exhibit 35
                                  ----------


                      COUNTRYWIDE HOME LOANS SERVICING LP


                             OFFICERS' CERTIFICATE
                    ANNUAL STATEMENT OF THE MASTER SERVICER


                                  CWALT, INC.
                       ALTERNATIVE LOAN TRUST 2007-HY8C
             MORTGAGE PASS-THROUGH CERTIFICATES, SERIES 2007-HY8C


         The undersigned does hereby certify that the undersigned is an
officer of Countrywide GP, Inc., general partner of Countrywide Home Loans
Servicing LP (the "Master Servicer"), and does hereby further certify pursuant
to Section 3.16 of the Pooling and Servicing Agreement for the above-captioned
Series (the "Agreement") that:

(i)   A review of the activities of the Master Servicer during the preceding
calendar year and of the performance of the Master Servicer under the
Agreement has been made under my supervision; and

(ii)  To the best of my knowledge, based on such review, the Master Servicer
has fulfilled all of its obligations under the Agreement in all material
respects throughout such calendar year.




/s/ Craig Baingo                                        Dated: March 14, 2008
-----------------

Craig Baingo
Executive Vice President, Finance
Blenda K. HAGBERG, petitioner, v. LAKES BROADCASTING GROUP, INC., et al.

No. 12-8585.

Supreme Court of the United States

April 15, 2013.

Petition for writ of certiorari to the Court of Appeals of Minnesota denied.
Office of Global Policy and Strategy 

Letter Exchange Involving Aspartame

The United States of America has concerns with respect to the World Health 

Organization’s (WHO) plan to conduct overlapping reviews of the food additive 

aspartame (INS 951, CAS No. 22939-47) in two WHO bodies: the International Agency 

for Research on Cancer (IARC) and the Joint Food and Agriculture Organization/WHO 

Expert Committee on Food Additives (JECFA). In our opinion, JECFA is better suited to 

assess any risk associated with the consumption of aspartame because it considers all 

relevant toxicological endpoints, including carcinogenicity. Furthermore, JECFA is the 

primary source of scientific advice for the Codex Alimentarius Commission (CAC) 

pertaining to food additives, which is aspartame’s primary use and thus important to 

Codex Member States that base their food safety measures on Codex Alimentarius food 

safety standards. For these and other reasons outlined in the US Letter to WHO on 

Aspartame, we believe that a JECFA review of aspartame would have a greater impact 

on food safety, and public health, than one conducted by IARC. 

On August 12, 2022, Mara Burr, director of the Office of Multilateral Relations in the 

Department of Health and Human Services’ Office of Global Affairs, sent a letter 

outlining these concerns to the WHO. She received a reply on September 29, 2022. For 

transparency, the FDA is posting both documents. See letters appended below.
Gregory Allen SPEARS, DOC #716895, Appellant, v. STATE of Florida, Appellee.

Case No. 2D18-1275

District Court of Appeal of Florida, Second District.

Opinion filed June 19, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
Larry Lorenzo O'BRYANT, Appellant, v. STATE of Florida, Appellee.

No. 4D19-354

District Court of Appeal of Florida, Fourth District.

[May 2, 2019]

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
人乳头状瘤病毒是什么?

人乳头瘤病毒是一种性传播病毒。它通过生殖

器接触(如阴道性交和肛交)传播。它也可以通

过皮肤接触传播。 至少50%有过性行为的人会

在一生中的某个时候感染人乳头瘤病毒。

为什么我没有听说过人乳

头状瘤病毒?

为什么我没有听说过人乳头状瘤病毒?

人乳头状瘤病毒不是新病毒。但是很多人对此

一无所知。大多数人没有任何症状。它可能会

自行消失,不会引起任何健康问题。

美国食品及药物管理局女性健康办公室

www.fda.gov/womens

谁会感染人乳头状瘤病毒?

任何曾与他人有过生殖器接触的人都可能感染。男人

和女人都可能会在不知情的情况下染上这种病,并将

其传播下去。由于可能没有任何迹象,一个人可能

已经感染此病毒,即使他或她已经多年没有发生性行

为。

如果您符合以下条件,则您更有可能感染:

• 过早发生性行为,

• 很多性伴侣,或者

• 有很多伴侣的性伴侣。

如果没有迹象,为什么我需要

担心人乳头状瘤病毒?

有超过100种不同的人乳头状瘤病毒,并不是所有的都

会导致健康问题。某些类型的人乳头状瘤病毒可能会

导致生殖器疣等问题。某些类型的人乳头状瘤病毒也

能引起子宫颈、阴道、外阴或肛门的癌症。这些问题

大多是由类型6、11、16或18引起的。

人乳头状瘤病毒可以治愈吗?

人乳头状瘤病毒本身没有治愈方法。对于人乳头状瘤

病毒可能引起的健康问题,如生殖器疣、子宫颈病变

和宫颈癌,有治疗方法。

关于生殖器疣我应该知道些

什么?

生殖器疣有多种治疗选择。 但是即使在治疗了疣之

后,该病毒仍可能存在并可能传播给他人。 如果不治

疗尖锐湿疣,它们可能会消失,保持原状或增大大小

或数量,但不会变成癌症。

人乳头状瘤病毒
人乳头状瘤病毒

这份情况说明书是由食品及药物管理局妇女健康办公室编写的。

要获得其他女性健康资源,请访问

www.fda.gov/womens

2021

关于子宫颈癌,我应该知道

些什么?

所有女性都应该定期做巴氏试验。巴氏涂片检查是

为了寻找由人乳头状瘤病毒引起的细胞变化。该测

试发现细胞在早期发生变化,所以宫颈癌可以在细

胞转化为癌症之前得到治疗。这项测试也可以在癌

症的早期发现它,所以可以在癌症变得太严重之前

得到治疗。如果及早发现,子宫颈癌致死率是很小

的。

关于阴道癌或外阴癌我应该

知道些什么?

阴道癌是阴道的癌症。外阴癌是阴蒂、阴道唇和阴

道开口的癌症。这两种类型癌症是非常罕见的。并

非所有的阴道癌或外阴癌都是由人乳头状瘤病毒引

起的。

关于肛门癌我应该知道些什

么?

肛门癌是在肛门组织中形成的癌症。肛门是直肠(

大肠的最后部分)向身体外部的开口。 

有针对人乳头状瘤病毒的

测试吗?

是的。 它检测可能导致子宫颈癌的人乳头状瘤病

毒类型。美国食品及药物管理局批准将人乳头状

瘤病毒检测用于30岁以上的女性。它甚至可能在

子宫颈发生变化之前就发现人乳头状瘤病毒。做

过人乳头状瘤病毒测试的女性仍然需要做巴氏涂

片测试。

我可以预防人乳头状瘤病

毒吗?

美国食品及药物管理局已经批准了预防某些疾病

的疫苗,包括子宫颈癌某些类型的人乳头状瘤病

毒。询问您的医生您是否应该接种人乳头状瘤病

毒疫苗。

我还能做什么来降低感染

人乳头状瘤病毒的机会?

•

• 如果发生性行为,您可以限制伴侣的数量。

•

• 目前还不清楚避孕套有多少作用预防人乳头状

瘤病毒。没有使用避孕套的区域可能会暴露在

病毒之下。

人乳头状瘤病毒 (CHINESE)
HEARTS BLUFF GAME RANCH, INC., petitioner v. TEXAS, et al.

No. 12-1015.

Supreme Court of the United States

April 22, 2013.

Petition for writ of certiorari to the Supreme Court of Texas denied.
Aaron JORDAN, petitioner, v. S. FULLER, et al.

No. 12-9450.

Supreme Court of the United States

May 28, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Tenth Circuit denied.
exv10wxjyxiiiy






Exhibit 10(j)(iii)




FIRST AMENDMENT TO APPENDIX F TO THE

NORTHROP GRUMMAN SUPPLEMENTAL PLAN 2 —

CPC SUPPLEMENTAL EXECUTIVE

RETIREMENT PROGRAM

(As Amended and Restated Effective January 1, 2005)




     This amendment to the January 1, 2005 restatement of Appendix F to the Northrop Grumman
Supplemental Plan 2 — CPC Supplemental Executive Retirement Program (the “Appendix”) addresses
certain new participants under this Program.



     This amendment is effective December 1, 2008.




	1.	 	A new paragraph is hereby added to the end of Section F.03 of the Appendix to read as
follows:
	 
	 	 	“Notwithstanding any other provision of this Program to the contrary, no additional
employees shall become eligible to participate in the Program after November 2008 unless the
Corporate Vice President, Chief Human Resources and Administrative Officer designates them
for participation in writing.”






	2.	 	A new Section F.10 is hereby added to the Appendix to read as follows:
	 
	 	 	“2008 Participants.
	 
	 	 	Any employee who first became a Participant in the Program after June 2008 shall cease to
accrue benefits under the Program as of December 31, 2008. The present value of the accrued
benefit of such a Participant shall be distributed in a lump sum payment in 2009, pursuant
to transition rules under section 409A of the Code. The present value shall be calculated
using the actual assumption and calculation procedures for lump sum distributions under the
Northrop Grumman Pension Plan.”





*      *      *




     IN WITNESS WHEREOF, this Amendment is hereby executed by a duly authorized officer on this
19  day of  Dec., 2008.



	 	 	 	 	 
	 	NORTHROP GRUMMAN CORPORATION

 	 
	 	By:  	/s/ Debora L. Catsavas
 	 
	 	 	Debora L. Catsavas 	 
	 	 	Vice President, Compensation, Benefits

and International
John WHALEY and Antonio Rivera, petitioners, v. William E. BRUST, et al.

No. 12-8846.

Supreme Court of the United States

April 22, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Second Circuit denied.
Thomas S. BRENNAN, petitioner, v. ILLINOIS.

No. 12-810.

Supreme Court of the United States

April 15, 2013.

Petition for rehearing denied.
Felicia Nicole JONES, petitioner, v. PLUS 4 CREDIT UNION.

No. 12-9650.

Supreme Court of the United States

June 10, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
ZURN PEX, INC., et al., v. Denise COX, et al.

No. 11-740 (R46-014).

Supreme Court of the United States

April 11, 2013.

The petition for writ of certiorari was dismissed today pursuant to Rule 46.1 of the Rules of this Court.
Developed by ORA/Office of Communications and Project Management/Division of Communications - 3/2022 

GOALS

A2LA Lab Accreditation, ISO/IEC 17025:2017 

Office of Regulatory Affairs 

Alaska Department of Environmental 

Conservation (ADEC) and FDA Partnership

MOU 225-20-007

Established 

Radionuclide 

Monitoring 

Capability

in response to 

the Fukushima 

nuclear power 

plant accident

THIS PARTNERSHIP AGREEMENT

enhances collaboration and avoids 

duplication of sampling efforts by 

state and federal agencies, thereby 

saving valuable resources. 

FINFISH SAMPLING

PARTNERSHIP AGREEMENT SUPPORTING DOCUMENTATION

1- Partnership Agreement Memorandum of Understanding - MOU 225-20-007

2- ADEC - Fukushima Radiation Concerns in Alaska

FDA loaned 

ADEC a Canberra 

Gamma-ray 

Detection System

to test for radionuclides 

in Alaskan coastal 

water finfish.

43 finfish 

samples were 

analyzed for 

radionuclides

Developed

Emergency 

Response

Capability

OBJECTIVES AND PURPOSE OF THE PARTNERSHIP AGREEMENT

RESULTS/OUTCOMES

43 TOTAL SAMPLES 

All were Lab Class 1 

for Gamma-ray 

emitting radionuclides 

except for naturally 

occurring Potassium 40

13 SAMPLES 

FY 2018

16 SAMPLES 

FY 2017

7 SAMPLES 

FY 2019

7 SAMPLES 

FY 2020

NOTE: The effect of COVID-19 impacted 

the FY 2020/2021 Partnership 

Agreement sampling efforts

THE FDA GAMMA-RAY 

DETECTION SYSTEM

ensures ADEC the capability to 

increase public health/safety in 

the event of a similar crisis.

Increased 

Public 

Health and 

Safety with 

consumption 

of finfish

FDA LOANED GAMMA-RAY DETECTION MACHINE RESULTS:

Benefits 

small 

fishing 

companies 

to compete 

in a global 

market

Increases & 

maintains 

seafoodrelated 

employment 

& earnings

Develop a 

nutrient & 

contaminant 

database 

for different 

fish species 

ADEC received 

an Extramural 

Industry Grant 

(SEPTEMBER 2021)
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

United States District Court

Northern District of California

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

WAYMO LLC,

Plaintiff,

v.

UBER TECHNOLOGIES, INC., et al.,

Defendants.

Case No.17-cv-00939-WHA (JSC)

ORDER RE: LIOR RON'S REQUEST 

FOR CLARIFICATION OF DOCKET 

NO. 1295

Re: Dkt. No. 1297

The Court is in receipt of Lior Ron’s Request for Clarification of the Court’s Order 

granting his motion for reconsideration. (Dkt. Nos. 1295, 1297.) Mr. Ron does not have to sit for 

a second day of deposition until after the Court of Appeals for the Federal Circuit rules.

IT IS SO ORDERED.

Dated: August 22, 2017

JACQUELINE SCOTT CORLEY

United States Magistrate Judge

Case 3:17-cv-00939-WHA Document 1298 Filed 08/22/17 Page 1 of 1
Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO EXCHANGE ACT RULES 13a-14(A) AND
15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David C. Scott, certify that:



|1. | I have reviewed this Annual Report on Form 10-K of 3PAR Inc.; and
|-- | -----------------------------------------------------------------



|2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report.
|-- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|                    |  |  |  |                                                
|------------------- |  |  |  | -----------------------------------------------
|Date: July 29, 2009 |  |  |  | /s/    DAVID C. SCOTT                          
|                    |  |  |  | David C. Scott                                 
|                    |  |  |  | President, Chief Executive Officer and Director
|                    |  |  |  | (Principal Executive Officer)
* This disposition is not appropriate for publication and is not precedent except as provided by 9th Cir. R. 36-3. NOT FOR PUBLICATION UNITED STATES COURT OF APPEALS FOR THE NINTH CIRCUIT
MUKESH SINGH, A# 73-218-766, Petitioner - Appellant,
v. ERIC H. HOLDER, Jr., Attorney General, Attorney General of the United States; et al., Respondents - Appellees. No. 10-35480 D.C. No. 2:09-cv-00397-JLR
MEMORANDUM *

Appeal from the United States District Court for the Western District of Washington James L. Robart, District Judge, Presiding Argued and Submitted February 10, 2011 Seattle, Washington Before: B. FLETCHER, PAEZ, and IKUTA, Circuit Judges. Mukesh Singh (“Singh”) appeals from the district court’s order denying his habeas petition, filed pursuant to 28 U.S.C. § 2241. We dismiss the appeal as moot. 

# FILED
MAR 02 2011 MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALSSimultaneously, with the filing of this or der, we filed an order in the related case of Singh v. Holder , No. 03-72088, granting Singh’s 2009 Motion to Reinstate Petition for Review. With the reinstatement of the Petition for Review, Singh has achieved all the relief that he seeks in the instant appeal. Accordingly, we dismiss the appeal as moot. DISMISSED.
Kenneth FERNANDES, petitioner, v. CARNIVAL CORPORATION, dba Carnival Cruise Lines, Inc.

No. 12-456.

Supreme Court of the United States

April 15, 2013.

Motion of Port Ministries International for leave to file a brief as *amicus curiae* granted. Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.
Reginald A. WILLIAMS, petitioner, v. COLUMBUS REGIONAL HEALTHCARE SYSTEM, INC., et al.

No. 12-1079.

Supreme Court of the United States

May 13, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.
##### 



Exhibit 31.2 CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Allan Frank, certify that:  1.
    
    I have reviewed this quarterly report on Form 10-QSB of Axcess
International, Inc.;2.
    
    Based on my knowledge, this quarterly report does not contain any
untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to
the period covered by this quarterly report;3.
    
    Based on my knowledge, the financial statements, and other
financial information included in this quarterly report, fairly present
in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented
in this quarterly report;4.
    
    The registrants other certifying officers and I are responsible
for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rule 13a-14 and 15d-14) for the registrant and
we have:  a)
    
    designed such disclosure controls and procedures to
ensure that material information relating to the registrant,
including its consolidating subsidiaries, is made known to us by
others within those entities, particularly during the period in
which this quarterly report was prepared;b)
    
    evaluated the effectiveness of the registrants
disclosure controls and procedures as of the end of the period
covered by this quarterly report (the Evaluation Date); andc)
    
    presented in this quarterly report our conclusions
about the effectiveness of the disclosure controls and procedures
based on the required evaluation as of the Evaluation Date;  5.
    
    The registrants other certifying officers and I have disclosed,
based on our most recent evaluation, to the registrants auditors and
the audit committee of registrants board of directors (or persons
performing the equivalent function):  a)
    
    all significant deficiencies in the design or operation
of internal controls which could adversely affect the
registrants ability to record, process, summarize and report
financial data and have identified for the registrants auditors
any material weaknesses in internal controls; andb)
    
    any fraud, whether or not material, that involves
management or other employees who have a significant role in the
registrants internal controls; and  6.
    
    The registrants other certifying officers and I have indicated in
this quarterly report whether or not there were significant changes in
internal controls or in other factors that could significantly affect
internal controls subsequent to the date of our most recent evaluation,
including any corrective actions with regard to significant
deficiencies and material weaknesses. Date: November 9, 2004 /s/ ALLAN L. FRANK
ឯក�រ�

ះផលិត�យ� �កស ុខ�ព� �ី(OWH) និងស�គម

�តិ��ងឱសថ�ល�ន� �ះដ ូច� �

(NACDS)�រដ ��លចំណី��រសរដ ���រ�ក(FDA) 

��ណ�30% �50% �អ � ក�ំង�យ�ះ�ល�ើឱសថ 

មិន�ន�ើ�ដ ូច�ល�ន��ំ�ះ�។ �ំង�ះប� �លឲ��

ន�រពិ�ះ�ម ួយ���ទ� �រ� �ក់�ក � �ងមន � ីរ�ទ� �រច ុះ

ទម �ន់ �រ�ត់បង ់�ក់ឈ � �លនិង�រ� �ស់ប � �រ�ជ � ប� �។ 

�ំងអស់�ះ� � ើឲ���ជន��រ�ក�តបង ់�ក់�ើន�ង 100 �ន់�

នដ ុ� �រក � �ងម ួយ� �ំ។

��ឿយៗ មន ុស��ញវ ័យ�រក�ឱសថស�ប់���រ�ំងម ួលនិង

ស�ប់ខ ្ឡ �ន�ផង�រ។ ដ ូ� �ះ�ើង��វ�ន� �ក �ៀស�ង

ប� � ស ួ រសំណ �រនិង�រក�កំណត់�។

1. សូម�ន��ក

ម ុននឹងអ � ក�បឱសថ�ម ួយ ស ូម�ន� �ក�។ � �ករបស់�

គ ួ រ�ប� �ញ�ប់:

ប� � ី�រ�ត ុផ�ំ - �សិន�ើអ � កដ ឹង� អ � ក�ន�តិកម � �ស់�

នឹង�រ�ត ុ�ម ួយ�ក � �ងឱសថ�ះ។ ស ូមក ុ ំ�ើ�។ ស ូមស ួ រ

����ទ�របស់អ � ក ឬឱសថ�រ�� ើម�ីយកឱសថ��ងវ �ញ។

�រ��ន - ច ូរ�ន�ំង�ះ�យ�ុង�យ័ត �។ 

�លបរ�ច�ទផុតកំណត់ - សូមកុំ�ើឱសថផុត�លកំណត់�ល�ន

ស�រ��ើដប។ ���ល��ង�ន�សិទ�ិ�ព�ៀត�ើយ។

ស�ប់ព័ត៌�នលម�ិតអំពីឱសថ សូមសួរ�ឱសថ�រ�របស់អ�ក។

2.�ៀស�ងប���ំង�យ

ឱសថ�ំង�យ�ចបង �រប� ��� ឬឥទ � ិពលប� �ប់បន� � ំដ ូច� 

�រ�ងមិនលក់ �រក � �តចង � �រ �រហ ូរ�ម ឈឺក�ល ឬកន � �ល

�ើ��ក។ ស ូមស ួ រអំពីឥទ � ិផលប� �ប់បន�ំ�ឱសថ�លអ � កកំព ុង

�ើ។ ស ូមពិ�ក��ម ួយ���ទ� 

ឱសថ�រ�ឬគិ�ន ុប� �យិ�របស់អ � ក។

ស ូម�ត់�ងឱសថរបស់អ � កឲ��ន�ួល។

ស ូមក ុ ំខក�នទទ ួល�នឱសថរបស់អ � ក

 ស ូមក ុ ំ�ករ��កឱសថរបស់អ � ក�ម ួយអ � កដ�។

 ស ូមក ុ ំទទ ួល�នឱសថ�ទីងង ិត។

 សូម�ើឱសថ�យ�ុង�យ័ត� 

ស�ប់ខ��នអ�ក...ស�ប់អ�ក�ំង�ះ�ល��វ�រអ�ក

សូមយក�ល�រក�

Oce of Women’s Health

www.fda.gov/womens

ស�ប់ខ��នអ�ក...ស�ប់អ�ក�ំង�ះ�ល��វ�រអ�ក

សូមយក�ល�រក�

Tiempo Para Cuidar

Su Salud

ឱសថរបស់ខ��ំ 
3. សូមសួរសំណ�រ�ំង�យ

• �ើឱសថ�ះ� �ះអ � ី? 

• �ើ�ន� �ះ� �ំ�ម� �ះ�ត ុផ�ំ�រឬ�?

• �ត ុអ � ីខ � � ំនឹង�ប� �ំ�ះ?

• ��ល��លខ � � ំគ ួ រ�ប�?

• �ើខ � � ំគ ួ រ�ប���ល�ពះទ�ឬ�ម ួយ��រ?

• �ើ��នស ុវត � ិ�ព��លផ ឹក��ម ួយ�?

• �សិន�ើខ � � ំ� �ច�ប� �ើខ � � ំគ ួ រ� � ើអ � ី?

• �ើខ � � ំគ ួ រ�បប៉ុ� �ន?

• �ើខ � � ំនឹង�ប�រយៈ�លប៉ុ� �ន?

• �ើប� �អ � ីខ � ះ�លខ � � ំគ ួ រ�ុង�យ័ត �?

�សិន�ើអ � ក�ន� ��ះឬបំ�ក ូន�យទឹក�ះ 

ស ូម� �ងរក�រ��ំពីម�ី �ស ុខ�ពម ុននឹង�ប� �ំឬ��របំប៉ន�ម ួយ។ 

ស ូមពិ�ក��ម ួយ���ទ� ឱសថ�រ�ឬគិ�នុប� �យិ�។ ព ួក�នឹងជ ួយអ � ក

�យក � ីរ�ក�យ។

សូម�ៀប�ប់នូវ�តិកម��ស់�មួយ 

���ទ� 

�ខទូរស័ព� 

4. សូមរក�កំណត់�នូវឱសថ�លអ�ក�ើ

�ស់

សូមគូសក��ង�អប់ស�ប់ឱសថ�លអ�ក�ើ:

 ��ំ�ស់��រ�នឬ��ំឈឺក�ល បំ�ត់�រចុក�ប់ឬ��ំប���ះកំ�

 ��ងៗ

 ��ំ��កហ��ី 

 ��ំ�ន់�សុីត

 ��ំ���យ 

 ��ំក�ក 

 ��ំរបប��រឬ��របំប៉ន��ំប���ះ

 ថប់ដ��ើម

 ��ំ�ងលក់ 

 ��ំវ��មុីន 

 �តិខនិជ 

 ��ំរុក��តិ

 ��ងៗ 

សូមរក��ទុក�ក��ង�បូបឬ����ើយប��ញ�����ទ�របស់អ�ក ឱសថ�រ�ឬគិ�នុប��យិ�។

��ះ:

សូម�ៀប�ប់នូវឱសថ�ល�ន�ជ�ប��របស់អ�ក

�ើខ��ំ�ប�ប៉ុ��ន? ខ��ំ�

ប�

��ល�?

ខ��ំ�ើ�

�ើម�ីអ�ី?

បំ�ញ�ើងវ�ញ

មួយ�ប់

400 mg

3ដងក��ងមួយ���យ�យរួច រ�កស��

ក់ 2

��ះ��ំ

របស់ខ��ំ

�លបរ���ទ

ឧ�ហរណ៍ XXXX

សូមឲ����ទ�របស់អ�ក ឱសថ�រ�ឬគិ�នុប��យិ��យ�រណ៍អំពីប��ធ�ន់ធ�រ�ឱសថ�រដ��លចំណី��រសហរដ���រ�ក(FDA)�មរយៈ�ខ1-800-FDA-1088.